Acebutolol therapy for ventricular arrhythmia. A randomized placebo-controlled double-blind multicenter study

Area of Science:

• Cardiology
• Pharmacology

Background:

• Ventricular ectopy poses a significant risk for cardiovascular events.
• Effective antiarrhythmic agents are crucial for managing ventricular arrhythmias.

Purpose of the Study:

• To evaluate the efficacy and safety of acebutolol in suppressing ventricular ectopy.
• To assess the dose-response relationship of acebutolol on ventricular premature complexes (VPCs).

Main Methods:

• Double-blind, randomized, crossover study involving 60 male patients.
• 24-hour Holter monitoring was used to quantify VPCs before and during acebutolol treatment.
• Acebutolol (200 mg and 400 mg thrice daily) was compared against a placebo.

Main Results:

• Over 50% of patients experienced >70% reduction in VPCs/hour with acebutolol.
• A dose-related decrease in VPCs and ventricular tachycardia episodes was observed (p<0.05).
• Significant, asymptomatic reductions in resting heart rate and blood pressure were noted.

Conclusions:

• Acebutolol demonstrates significant efficacy in suppressing ventricular ectopy.
• The drug is well-tolerated, with transient side effects reported in only one patient.
• Acebutolol is a safe and effective treatment option for selected patients with ventricular arrhythmias.